Deutsche Bank Aktiengesellschaft Cuts Eli Lilly and Company (NYSE:LLY) Price Target to $1,015.00

Eli Lilly and Company (NYSE:LLY) had its price target cut by Deutsche Bank Aktiengesellschaft from $1,025.00 to $1,015.00 in a report issued on Monday, Benzinga reports. They currently have a buy rating on the stock.

LLY has been the subject of a number of other research reports. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Bank of America dropped their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $776.47 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market capitalization of $737.11 billion, a price-to-earnings ratio of 83.94, a PEG ratio of 3.05 and a beta of 0.43. The firm’s 50 day simple moving average is $901.75 and its 200-day simple moving average is $867.32. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. Analysts expect that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LLY. China Universal Asset Management Co. Ltd. raised its stake in shares of Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares during the period. Quent Capital LLC lifted its stake in Eli Lilly and Company by 5.3% during the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares in the last quarter. Mutual Advisors LLC boosted its position in shares of Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after buying an additional 50,197 shares during the period. Whittier Trust Co. boosted its position in shares of Eli Lilly and Company by 52.2% during the first quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock worth $58,725,000 after buying an additional 25,877 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of Eli Lilly and Company by 155.1% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after buying an additional 12,004 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.